2016 Career Advisory Network (CAN)

Schedule & Mentor Bio

Chinese American Bio/Pharmaceutical Society

Business and Development Committee

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>04/01-04/16</td>
<td>Online Application</td>
</tr>
<tr>
<td>04/17-04/30</td>
<td>Screening and Matching Process</td>
</tr>
<tr>
<td>May</td>
<td>1:1 Mentoring - 1</td>
</tr>
<tr>
<td>June</td>
<td>1:1 Mentoring - 2</td>
</tr>
<tr>
<td>July</td>
<td>Midterm Panel Discussion &amp; Mixer</td>
</tr>
<tr>
<td>August</td>
<td>1:1 Mentoring - 3</td>
</tr>
<tr>
<td>September</td>
<td>1:1 Mentoring – 4</td>
</tr>
<tr>
<td>October</td>
<td>Graduation (Format T.B.D)</td>
</tr>
</tbody>
</table>
Mentor List

- **Ying Gong, Ph.D.** Medical Affairs, Strategic Planning and Business Operations, Genentech
- **Zhengtian (Titan) Gu, Ph.D.** Vice President and head of Analytical Development and Quality Control, Theravance Biopharma
- **Alan Hao, Ph.D.** Founder, AIM Biosciences Inc.
- **Dr. Cheni Kwok**, Managing Partner and Founder, Linear Dreams LLC
- **Zheng (Jen) Liu, J.D.**, of counsel, Orrick
- **Jiangwen Majeti, Ph.D. MBA**, Global Category Manager for Biomarkers and Companion Diagnostics, Genentech, a Roche group
- **Shichang Miao, Ph.D.**, Executive Director, ChemoCentryx Inc
- **Wentao Zhang, Ph. D.**, Founder, Quintara Discovery
- **Hing Sham, Ph.D.** Senior Vice President-Chemistry, Global Blood Therapeutics
- **Xiaoli Qin, Ph.D.** Senior Director of Research at Curegenix
- **Dannis Chang, PharmD**, Medical science director, Genentech
- **Qiang Chen, Ph.D.**, Quality Product Leader, Genentech
- **Charlene Liao, Ph.D.** Project Team Leader, Genentech
- **Shelly Xiong, Ph.D., RAC**, Vice President of Regulatory, Eiger BioPharmaceuticals, Inc.
- **Zhenhai Shen, Ph.D., MBA**, Director of Alliance Management, Genentech Partnering group
- **Kedan Lin, Ph.D.**, Senior Scientist and Therapeutic Area Leader, Genentech
- **Lin Sun-Hoffman, Ph.D. J.D.**, President at Sun-Hoffman Consulting
- **Meijie Tang, Ph.D.** co-founder, CEO, Nirmidas Biotech
- **Jessica Sun, M.D., Ph.D.**, Director of In Vivo Biology at Reset Therapeutics
- **Guo-Liang Yu, Ph.D.**, executive Chairman, Crown Bioscience Inc.
- **Yingfei Wei, Ph.D., 3SBio**
- **Zhengping Wang, Ph.D.** Scientific Director of Pharmacokinetics and Drug Metabolism (PKDM), Amgen
- **Alex Zhang, Ph.D.**, co-founder and COO, Enverest
- **Mingfu Zhu, Ph.D.**, Bioinformatics Scientist, Human Longevity Inc
- **Victor Lee, Ph.D.**, Life Sciences Business Executive & Attorney
- **Dongliang Ge, Ph.D.** Director of Bioinformatics, Gilead Sciences
- **Jingyi Xiang, Ph.D.** Head of Bioanalytics, Eureka Therapeutics
- **Shawn Lee, Ph.D.** vice-Chairman, Xinbang Pharmaceutical; Chairman of the Board, CPC Hangzhou
- **Steven Cui, Ph.D., J.D.** TransPac IP
Mentor Bio

**Ying Gong, Ph.D.**, received her PhD in Biochemistry and Molecular Biophysics from Caltech, studying the molecular mechanisms of vertebrate morphogenesis using zebrafish as a model. Upon graduation, she joined the management consulting firm Bain & Company, where she worked on a broad range of business strategy and operations projects in different industries. Dr. Gong joined Genentech in late 2007, where she has been responsible for commercial strategies of R&D programs in a number of therapeutic areas. Recently, she moved to a new position within Genentech and is responsible for developing reimbursement strategies.

**Zhengtian (Titan) Gu, Ph.D.** is currently a Vice President and head of Analytical Development and Quality Control at Theravance Biopharma, South San Francisco, CA. Titan has close to 20 years of research and development experience in the pharmaceutical industry. He received his college education at University of Science and Technology of China, and his Ph. D. in Biophysical Chemistry from Columbia University in 1996, with postdoctoral fellowships at Memorial Sloan Kettering Cancer Center and University Pennsylvania, where he was a fellow of Leukemia Society of America. Since 1998, he has had various managerial and scientific positions at Theravance, 3M, GlaxoSmithKline and Procter & Gamble Pharmaceuticals. Dr. Gu has in depth experience in Chemistry, Manufacturing and Control (CMC) and preclinical development areas for IND and NDA filing. He made significant contributions to the successful approval of Vibativ in US, Europe, Canada and Russia.

**Alan Hao, Ph.D.** is a seasoned medicinal chemist with the passion of discovering innovative medicines to treat diseases with unmet need. He worked on various disease areas including cancer, inflammation, diabetes and obesity in Tularik and Amgen. During his industrial career over the past 15 years, Alan was responsible for providing scientific and technical leadership and strategic direction to the medicinal chemistry projects, and led the medicinal chemistry efforts to move three drug candidates into clinical trials. Most recently, Alan founded AIM Biosciences, with the goal of developing affordable innovative medicines for seriously ill patients. He received his PhD in organic chemistry from the University of Illinois at Chicago and BS from Peking University. He was the president of CABS in 2014-2015.

**Ruhong Jiang, Ph.D.**, is cofounder and CEO of Applied StemCell, Inc. - a global leading company in gene editing and stem cell areas, located in San Francisco Bay area. He has held a variety of technical and managerial roles with increasing responsibilities in several biotechnology/biopharmaceutical companies. Before starting Applied StemCell, Ruhong was general manager of MicuRx (Shanghai) Pharmaceutical, Inc. a California - based biopharmaceutical company where he set up its entire China operation. From 2005 - 2007, Dr. Jiang was head of the Pharmacogenetics Program at Stanford Research Institute International.
(SRI) where he managed multiple pharmacogenetic and molecular genetics projects with multi-millions of annual budget. Prior to relocating to California, Dr. Jiang was pharmacogenomics consultant at Boehringer Ingelheim Pharmaceuticals and served as senior scientist, then project manager at Genaissance Pharmaceuticals from 2000-2004 where he played an important role in biomarker discovery, pharmacogenetics and clinical bioinformatics, diagnostic product development, alliance management and business development. Dr. Jiang graduated from Fudan University with a B.S. degree in biology, and received M.S. degree in reproductive biology from China Agricultural University and a Ph.D. degree in Genetics from Oklahoma State University in 1997. From there Ruhong went to Baylor College of Medicine where he furthered his education as a postdoctoral fellow in Dr. Douglas Burrin’s lab. Dr. Jiang has authored and co-authored more than 40 publications in the fields of human genetics, pharmacogenetics and disease animal models. Ruhong has a deep interest in the science, ethics and societal issues of personalized medicine, regenerative medicine and global health. His demonstrated leadership has led to an established track record of success; especially in the areas of biomarker-based molecular assays or diagnosis, CRO service, and drug research and development.

**Dr. Cheni Kwok**, is a Managing Partner and Founder of Linear Dreams LLC, a management consultancy and valuation software firm specialized in corporate strategy, business/corporate development, portfolio analysis, and valuation services for the life science industry. Prior to founding Linear Dreams LLC, Dr. Kwok served as Senior Vice President, Corporate Development at Poniard Pharmaceuticals Inc., where she established corporate and business development, strategic and commercial planning, new product planning, competitive intelligence and forecasting functions. Previously, Dr. Kwok was Director of Business Development at Celera Genomics Inc., where she led the business development efforts for Celera's small molecule therapeutics. Dr. Kwok held business development positions of increasing responsibility for Exelixis Inc., where she initiated multiple partnerships and served as the alliance manager for the GlaxoSmithKline PLC (GSK) collaboration. Prior to joining Exelixis Inc., Dr. Kwok held various research management, technology assessment and alliance management roles at SmithKline Beecham PLC (now GSK). Dr. Kwok received a bachelor's degree in biotechnology from the Imperial College of Science, Technology and Medicine, University of London, UK, and a Ph.D. in human molecular genetics from the University of Cambridge, UK. Dr. Kwok has earned the Certified Licensing Professional (CLP) credential awarded by the Licensing Executives Society.

**Zheng (Jen) Liu, J.D.,** an of counsel in the Silicon Valley office, Orrick, is a member of the Intellectual Property Group. Ms. Liu’s practice focuses on patent, trade secrets, and unfair competition litigation, intellectual property counseling, due diligence and technology transactions across a broad range of industries, including biotechnology, pharmaceutical, medical devices, Internet and telecommunications. Before joining Orrick, Ms. Liu was an associate at a prominent IP litigation boutique firm, where she was involved in matters for Amgen Inc.,
Angiotech Pharmaceuticals Inc., Isis Pharmaceutical Inc., Napo Pharmaceuticals, Inc., and Lilly ICOS LLC. Ms. Liu worked in anti-viral drug development at Johnson & Johnson between graduate school and law school, therefore understands the science and process of drug development as well as the business objectives of corporations. Ms. Liu was born and raised in China. She has served on the Executive Committee of the Berkeley Chinese Alumni International Association and on the board of the University of Science & Technology (USTC) Alumni Association. She was also the recent former President and current board member of Chinese Lawyers' Association in the Bay Area (CALOBA). She has been active in promoting mutually beneficial legal and business relationships between the United States and China, helping Chinese law students and junior lawyers succeed in the United States, and lecturing Chinese companies and technology associations on legal issues faced by Chinese companies or professionals. She also writes articles for Chinese language publications, such as the prestigious Caijing magazine, on issues of U.S. law. She also provides pro bono legal services for victims of domestic violence.

Jiangwen Majeti, Ph.D. MBA is currently the Global Category Manager for Biomarkers and Companion Diagnostics at Genentech, a Roche group. Prior to joining Roche, she was the Senior Director of Business Development at BioDuro, a PPD company. She transitioned from a senior research scientist position at Amgen to the business development role at BioDuro after the completion of her MBA in 2011. She brings over 10 years drug discovery experience in the biopharmaceuticals industry to her current post. While at Amgen, Dr. Majeti led research efforts in both small molecule and biologics drug discovery programs. Prior to joining Amgen, she was a scientist in the Discovery Biology Group at GPC Biotech, Waltham, MA. Dr. Majeti graduated from Fudan University, China with a B.S. in Biochemistry and holds a Ph.D. in Molecular Genetics from the University of Wisconsin at Madison followed by postdoctoral training at the Howard Hughes Medical Institute at the University of California, San Francisco. She also holds a MBA degree from Leavey School of Business at Santa Clara University.

Shichang Miao, Ph.D., is a past president of CABS (2009-2010). He is employed as Executive Director, Discovery & Clinical Drug Metabolism / Pharmacokinetics at ChemoCentryx Inc., a public biotech company focusing on the drug discovery and development through regulation of chemokine receptors. Previously, he was a director in the pharmacokinetics and drug metabolism department at Amgen South San Francisco. He worked at Tularik Inc. from 1994 through 2004 (most recently as Associate Director, Analytical Chemistry and Drug Metabolism) until Tularik's acquisition by Amgen. He holds a Ph.D. in organic chemistry / natural products chemistry from the University of British Columbia (Vancouver) and carried out postdoctoral research in organic chemistry and biochemistry. In addition to his CABS leadership activities, he is also the founder and president of Pharmaceutical & BioScience Society.
International (PBSS), a professional organization of 5000+ members with chapters in the San Francisco Bay Area, San Diego, Boston, Vancouver and Korea.

**Wentao Zhang, Ph. D.,** is Founder of Quintara Discovery, a biotech company focusing on drug discovery and development services that include in vitro ADME, bioanalysis and assay development in South San Francisco. Quintara Discovery has been working and collaborating with over 100 biotech and pharmaceutical companies and institutions, including the NIH, Stanford, and UCSF. Dr. Zhang has shown keen interest in entrepreneurship and has invested in several start-up companies. Previously, Dr. Zhang was Senior Director of Lead Discovery at Exelixis from 2001 to 2012, managing key drug discovery platform and functions that include compound library management, assay development and high-throughput screen efforts, lead optimization and ADME operations. Dr. Zhang has worked extensively in targeted drug discovery covering kinases, GPCR’s and nuclear hormone receptors using a wide spectrum of enabling technologies. The drug discovery technology platform that Dr. Zhang helped to establish has generated and progressed over 20 compounds from discovery to clinical development, including cabozatinib and cobimetinib, two kinase inhibitors approved by the FDA for cancer. Before that, Dr. Zhang was a Staff Scientist at Genelabs Technologies from 1999 to 2001 responsible for biochemical and biophysical assays in the therapeutic areas of oncology and infectious diseases. In 1997-1999, Dr. Zhang was a postdoctoral fellow at University of California-Berkeley. He obtained his Ph.D. from University of Wisconsin-Madison, M.S. from Emory University and B.S. from Peking University. Dr. Zhang has published extensively in peer-reviewed scientific journals and holds multiple patents. He has been actively involved in various professional services and organizations, including serving on the NIH study section on assay development. Dr. Zhang has extensive management experience and has played key leadership roles in various biopharmaceutical companies. Dr. Zhang was President of the Chinese-American Biopharmaceutical Society (CABS) in 2012-13.

**Hing Sham, Ph.D.,** has 33 years of drug discovery experience in five therapeutic areas including neuroscience, oncology, infectious diseases, metabolic diseases and cardiovascular diseases, delivering multiple clinical candidates for clinical development; inventor of two HIV drugs (Norvir and Kaletra, both HIV Protease inhibitors) that were approved by the FDA and EMEA, with one of them (Kaletra) having blockbuster sales (over a billion dollars per year) every year since 2005. Named National Inventor of the Year in 1997 by Intellectual Property Owners-Washington DC; named Inventor of the year two times by the Intellectual Property Law Association of Chicago (1997 & 2004); named Hero of Chemistry by the American Chemical Society in 2003 for the invention of Kaletra; named the 2011 Distinguished Alumni by the University of Hawaii Alumni Association; recipient of the CABS K. Fong award in 2014. From 2006 to 2012, Dr. Sham led the drug discovery effort at Elan in the area of Parkinson's and Alzheimer's diseases as the Head of the Chemical Sciences department until November 2012. Until July 2014, Dr. Sham is the Head of Research and preclinical development at PATH-a non-
profit organization, responsible for finding novel therapeutics for diseases that are of particular high burden in developing countries e.g. diarrheal diseases. His specialties include medicinal chemistry; drug discovery; structure based drug design; project management. Currently Dr. Sham is the senior vice president at Global Blood Therapeutics working on orphan diseases such as sickle cell diseases, hereditary angioedema.

**Xiaoli Qin, Ph.D.** currently is Senior Director of Research at Curegenix, Inc, an innovative therapeutic development company concentrating on novel anti-cancer therapeutic agents. She leads the biology program on drug development, focusing on biomarker for pre-clinical studies and clinical trials. Dr. Qin has more than 10 years of experience in translating biomarker knowledge into clinical applications. Prior to joining Curegenix, Dr. Qin was Senior Scientist with increasing roles in clinical biomarker development and clinical virology at InterMune, Inc. Dr. Qin served on the Executive Council of Chinese American Biopharmaceutical Society (CABS), co-chairing the Business and Career Development Committee 2012 - 2014. She completed the business training at the Program in Innovation and Entrepreneurship at Stanford University School of Business targeted toward Silicon Valley innovators, scientists, and engineers working to gain greater understanding of the pathways to commercializing innovations and to learn general management skills. Dr. Qin received her B.S. degree from Peking University and her Ph.D. degree in Microbiology & Immunology through Stanford University School of Medicine. She conducted post-doctoral research in functional genomics and systems biology with Dr. Gerald M. Rubin at University of California, Berkeley.

**Dannis Chang, PharmD** received his Bachelor of Science in Molecular and Cellular Biology from UC Berkeley. After receiving his undergraduate degree, he worked in project management at Genentech in the Translational and Molecular Oncology Division, as well as a researcher at LifeScan Inc. After several years in the workforce, he returned to school and received a doctorate of pharmacy degree from the University of Southern California School Of Pharmacy and completed a 2 year post-doctoral PharmD Fellowship with Novartis Oncology in US and Global Clinical Development and Scientific Affairs Division. During his time at Novartis, he rotated through various departments such as US and Global Medical Information Services, Field Medical Operations (MSLs), Managed Markets and Payer Access, and Scientific Communications. He also served as an adjunct faculty at the Ernest Mario School of Pharmacy at Rutgers University. Dannis joined Genentech Inc. in May 2012 as a senior product specialist in Medical Communications for Avastin, with a focus in lung, renal cell, and gynecologic cancers. Currently, he is the medical science director serving as the scientific lead for the cancer immunotherapy franchise within US Medical Affairs. His experiences in the bio-pharmaceutical industry comprise of multiple therapeutic areas including oncology, hematology, and immunology.
**Qiang Chen, Ph.D.** currently is Quality Product Leader at Genentech, Inc., a member of Roche Group. He serves as the end-to-end quality oversight of several small molecule clinical development projects. Dr. Chen has 18 years of industrial experience in the areas of pharmaceutical development, medical device, combination products for both traditional dosage forms and innovative delivery technology. Prior to joining Genentech, Inc., Dr. Chen served for several companies in Bay Area mainly in Quality and Analytical Sciences. Dr. Chen was Director of Analytical Development at Allergan (2012-2013), Senior Director of Quality Control at Alexza Pharmaceuticals, Inc. (2004-2011), Senior Scientist at Corium International (2002-2004), Sr. Manager of Analytical Sciences at Cygnus Inc. (1997-2002). Dr. Chen also served as President of United Chinese University Association in 2013, and has served as President of Xiamen University Alumni Association in Silicon Valley since 2010. Dr. Chen completed his undergraduate and graduate from Xiamen University and taught analytical chemistry for 6 years at Xiamen University before coming to the US pursuing his PhD degree. Dr. Chen received his PhD degree from New Mexico State University in 1995. He then conducted post-doctoral research in biosensor development with Dr. Adam Heller at University of Texas at Austin between 1995 and 1997.

**Charlene Liao, Ph.D.** holds Ph.D. in Biology from Brandeis University and a B.S. in Biochemistry from Peking University. She conducted postdoctoral research in immunology and signal transduction at UCSF where she was a Fellow of the Damon Runyon Cancer Research Fund and a Special Fellow of the Leukemia and Lymphoma Society of America. Dr. Liao began her bio-pharmaceutical industry career at Tularik Inc. (now Amgen) as a Scientist. Prior to joining Genentech Dr. Liao held various leadership positions at Rigel Inc., including Project Leader, Associate Director, and Director of Business Development. Dr. Liao joined Genentech in 2002 and has been a Project Team Leader since 2007. She has contributed to IND filing for 9 NMEs including large and small molecule drugs and across the therapeutic areas of oncology, immunology and infectious diseases. Dr. Liao is one of the founding members and Board of Directors of the Ray Wu Memorial Fund, and a part of the "Executive Program for Women Leaders" at Stanford Graduate School of Business.

**Shelly Xiong, Ph.D., RAC** is currently the Vice President of Regulatory at Eiger BioPharmaceuticals, Inc. She has over 20 years of pharmaceutical industrial experiences across a broad spectrum of drug development processes. She has extensive experiences in drug discovery, clinical development, regulatory strategy, and commercial activities. Prior to Eiger BioPharmaceuticals, she held various leadership positions at InterMune (Director of Regulatory Affairs), Gilead Sciences (Associate Director of Regulatory Affairs; Principal Scientist in Clinical Virology) and Covance (Director of China Operations). She was also a co-founder and Chief Scientific Officer of a start-up company. She received her Ph.D. in Biochemistry from University of Wisconsin-Madison and B.S. in Chemistry from Beijing University.
Zhenhai Shen, Ph.D., MBA, is current Director of Alliance Management at Genentech Partnering group. He received his Ph.D. Degree from The Mount Sinai School of Medicine and completed his postdoctoral training at DanaFarber Cancer Institute. Zhenhai also holds a MBA degree from Ross School of Business of University of Michigan. Prior to Genentech, Zhenhai worked in Eli Lilly's International Finance group.

Kedan Lin, Ph.D. is a Senior Scientist and Therapeutic Area Leader for Oncology Large Molecules in the Department of Pharmacokinetics & Pharmacodynamics at Genentech. She has fifteen years of discovery and development experience in both small molecules and biologics. Her group is responsible for characterizing PKPD properties for oncology large molecules and applying integrated quantitative pharmacological approach in selecting and optimizing novel therapeutics. She also leads multiple pharmacology teams for antibody drug conjugates, and her teams are responsible for overall pharmacology support from discovery to clinical development. Prior to Genentech, she held positions of increasing responsibilities at Celera Genomics and Exelisix. Kedan received her Ph.D. from University of California, San Francisco.

Dr. Sun-Hoffman is a licensed US patent attorney. She currently consults in biotech, pharmaceutical legal areas. Dr. Sun-Hoffman held positions at Life Technologies Corporation formerly Applied Biosystems as a Senior Patent Attorney and as a managing patent attorney at Celera Genomics. She obtained Celera’s first patent. She is also a former United States Patent and Trademark Office (USPTO) patent examiner. She has more than 10 years of biomedical research experience including several years as a postdoctoral research fellow with several publications at National Institutes of Health (NIH) in Frederick and Bethesda, Maryland. She currently serves legal consultant for companies in US, China, Taiwan and Japan. Dr. Sun-Huffman also drafts and negotiates contracts with various kind of the deals. She also helps company on regulatory issues in China. She has given many talks in SIPO and WIPO with USPTO delegation. She was president of Chinese Bioscience Association in 2013. Previously, she was Biotechnology Industry Organization’s (BIO) Chief Advisor for Asia and president of Chinese BioPharmaceutical Association, as well as Chief Representative for China Medical City, Taizhou, Jiangsu. Currently, she serves as Vice Chair of LES International University-Industry-Government subcommittee. Dr. Sun-Hoffman has a Juris Doctor (J.D.) degree and Ph.D. degree in Biochemistry/Cell and molecular Biology. Dr. Sun-Hoffman is admitted to the Maryland Bar and she’s registered to practice before the U.S. patent and Trademark Office.

Dr. Meijie Tang is the co-founder and currently the chief executive officer of Nirmidas Biotech, Inc., a life science technology platform company engaging in the development and commercialization of products to amplify signals for life science research, in vitro diagnostics and in vivo imaging. The company is a spin-off from Stanford University and is a StartX member. Before founding the company, she worked at Lawrence Livermore National Laboratory (LLNL) as a staff scientist and later project manager for 18 years. At LLNL, she had experience
and responsibilities building teams and leading multidisciplinary projects. In 2014, she left LLNL to become an entrepreneur. She studied physics in Tsinghua University (Beijing) as an undergraduate. Then went to MIT to study and conduct research on computational materials science. She obtained her PhD in 1995 from MIT. Dr. Tang’s technical expertise is in the areas of solid state physics, material science/nanoscience, and biotechnology. She has numerous publications in peer-reviewed journals and has career experience in scientific research, project and team management and startup growth.

Jessica Sun, M.D., Ph.D is a Director of In Vivo Biology at Reset Therapeutics. She has over ten years’ drug discovery and development experience in both small molecules and biologics. Her responsibility is to head in vivo screening, translational research, and biomarker development from discovery to early clinical development. In the last 20 years, she has gained experience in different disease area including renal disease, hematologic malignancy, solid tumors, inflammation disease, and recently the disorders associated with circadian rhythms. Prior to Reset, she held positions of increasing responsibilities at Threshold Pharmaceuticals and Y’s Therapeutics. Jessica received her Ph.D. on Medical Sciences from Hamamatsu University School of Medicine and completed her postdoctoral training at Stanford University School of Medicine. She started her profession as a board certified practice physician and a lecturer in China Medical University and its affiliated hospital.

Guo-Liang Yu, Ph.D., is executive Chairman, Crown Bioscience Inc., an emerging biotech company with 400 employees dedicated to the development of personalized cancer therapeutics. Guo-Liang cofounded Epitomics, a leading monoclonal antibody company. Guo-Liang was Senior Vice-President of Research and Development at Mendel Biotechnology Inc. where his team analyzed the function of a complete set of plant transcription factors by knock-out and over-expression in planta. Guo-Liang was a Senior Scientist at Human Genome Sciences Inc. where he discovered the target Blys for the lupus drug belimumab. Guo-Liang was trained at Harvard Medical School as a postdoctoral fellow and earned a Ph.D. degree with Nobel Laureate Dr. Elizabeth Blackburn in Molecular Biology from the University of California, Berkeley and B.S. degree in Biochemistry from Fudan University in Shanghai. Guo-Liang is a co-inventor of more than 200 patents and a co-author of 40 scientific articles. Guo-Liang is the founding president of Chinese Biopharmaceutical Association and service on several professional organizations in the US and China as a member of the board of directors or board of advisory.

Yingfei Wei, Ph.D., joined 3SBio in August 2006. She has over fifteen years of research and development experience in the biotechnology and pharmaceutical sectors. Before joining 3SBio, Dr. Wei was the Co-founder, President and Chief Executive Officer of Elixirin Corporation from 2004 to 2005, responsible for overseeing contract research, manufacturing, regulatory approvals and marketing of anti-aging products in the U.S. and China. Prior to that,
she was Director of Biotechnology Research at Bayer HealthCare Global from 1998 to 2004 and group leader at the discovery research department of Human Genome Sciences Inc. from 1993 to 1998. Dr. Wei is the inventor of 37 patents and has authored several publications, primarily in the areas of protein and antibody drug discovery and genomics. Dr. Wei was a postdoctoral fellow at Harvard University’s School of Public Health in 1993.

Zhengping Wang, Ph.D. is currently Scientific Director of Pharmacokinetics and Drug Metabolism (PKDM) at Amgen. Prior to this, she was director of DMPK at Onyx Pharmaceuticals. She was a key member in the development of Kryprolis, a new generation proteasome inhibitor for the treatment of multiple myeloma that was first accelerated approved in US in 2012 and gained full approval by FDA and EMA in 2015. Prior to Onyx, Dr. Wang was Senior Scientist at Proteolix.

Alex Zhang, Ph.D. is the co-founder and COO of Enverest, an innovative business expertise sharing platform helping Chinese and Asian companies to innovate and globalize. With more than 16 years of marketing, corporate management, business development and M&A experience in life sciences, Alex has helped many enterprises achieve accelerated growth and sustained global success. He was a consultant at LabMaven, helping Chinese contract manufacturing organizations develop business strategies in US and Europe. Prior to LabMaven, he led projects in corporate alliance, M&A integration, and global marketing at Thermo Fisher Scientific. Alex played a key role in a number of high profile acquisitions. Earlier in his career, Alex was a senior scientist at biotech giant Amgen. Alex has served on the Executive Council of the Chinese American BioPharmaceutical Society (CABS) since 2007. He is also a member of BayHelix, an organization of leaders of Chinese heritage in the global life sciences and healthcare community. Dr. Zhang graduated from Cornell University, Texas A&M University, and Shandong University.

Dr. Mingfu Zhu is a Bioinformatics Scientist at Human Longevity Inc, a world-leading genomics company founded by Craig Venter. Previously Dr. Zhu was the Director of Bioinformatics at Centrillion Biosciences, where he led the bioinformatics team for the development of a direct-to-consumer genetic testing product. Before joining Centrillion, he was the Director of Bioinformatics at Tute Genomics, and Assistant Professor in the Center for Human Genome Variation at Duke University School of Medicine. He completed postdoctoral training in bioinformatics at Duke University. He obtained his Ph.D. in mathematics from Clemson University in 2009 and BS in mathematics from University of Science and Technology of China in 2003. Dr. Zhu’s career path is lying solely in startups, having worked as an individual contributor and a manager. Working at a startup can be risky but rewarding, and choosing a right startup is particularly important. For those who is interested in working in startups, his experience can be valuable.
**Victor Lee, Ph.D.** has spent his entire professional career in the life sciences. He started as a scientist in cancer research, and became an attorney specializing in intellectual property (IP) and technology transactions. His most recent position was VP & Chief IP Counsel at Celera Corporation, a publicly-traded company focused on molecular diagnostics and genetic testing. As part of Celera's executive team, he was involved in many strategic decisions of the company. The progression of his career allowed him to acquire new skills from the diverse experiences at every stage. These experiences have expanded his competencies and made him particularly effective in contributing to companies that rely on IP protection, because he understands both the mindset of a scientist working in a lab and the daily challenges of an executive operating a business, as well as the expectations outside investors. Over the past 20 years, he has helped universities, start-up ventures, public companies, and international corporations in building and commercializing their IP portfolios.

**Dr. Dongliang Ge** is Director of Bioinformatics at Gilead Sciences after being Assistant Professor at Duke University. Named by the Genome Technology magazine as “rising stars” in 2009, his work predicting hepatitis C treatment response with IL28B genetic variants, published in Nature, has been commercialized and cited over 2000 times.

**Dr. Jingyi Xiang** has over fourteen years of experience in biomedical research, with in-depth knowledge and expertise in therapeutic antibody analytics. For the past four years as Head of Bioanalytics at Eureka Therapeutics, Dr. Xiang has led a team responsible for the detailed biochemical and biophysical characterization of more than a dozen therapeutic monoclonal antibody candidates. He has also been involved with the development of novel T-cell immunotherapy targeting intracellular cancer antigens. Dr. Xiang received his B.S. in Chemistry from Peking University, Ph.D. in Biochemistry from the State University of New York at Stony Brook, and postdoctoral training at UC Berkeley.

**Dr. Shawn Lee** serves as vice-Chairman of Xinbang Pharmaceutical (Stock# 002390). Xinbang is a Healthcare company operating in Pharmaceuticals, Hospitals, Biotech services and Medical devices. He founded Chinese Peptide Company (CPC Hangzhou) in 2001 and currently serves as its Chairman of the Board. It is the first peptide CRO out of China and premier peptide CRO/CMO in the world today. CPC’s 210,000 sf cGMP facilities have passed many successful inspections, CFDA and US FDA. Among its several hundred clients are top twenty pharmaceutical companies, innovative biotech companies and renowned scientific institutions. Peptide drugs/devices CPC supported have gained approvals in China, Singapore and Europe. Many of CPC’s IVD/POCT devices have 510K and clear waive status within FDA. He has substantial experience in entrepreneurship, corporate finance, technology transfer, licensing and business development. Dr. Lee also serves as CEO of CPC Scientific Inc, a Silicon Valley company he found in 2005. He is actively supporting other startup companies as partner of SVC Angel, Haibang Venture.
Steven X Cui (崔轩) grew up in Beijing and went to the University of Science & Technology of China for college. He came to the States to continue his pursuit in life sciences and obtained his PhD in neuroscience from the University of Illinois at Urbana-Champaign. During his graduate study, however, Steven decided to make a career move and went on to get a JD degree from Stanford Law School. Since then, he has been an IP practitioner, mainly working in biotech and pharmaceutical areas. For the past two decades, Steven’s path has spanned from private practice to in house, from US to China, from big firm to solo. He has held various managerial responsibilities in the roles of summer intern mentor, in house director, law firm of counsel and partner. Currently Steven runs his own firm TransPac IP, which focuses on China-related IP matters for US clients. Steven is also an on-site consultant for Genentech, the company he used to work at as an in house counsel.